A study on a biochemical marker in a disease called Multiple Myeloma
Not Applicable
- Conditions
- Health Condition 1: null- This prospective study will be conducted on total of 50 cases of bone marrow trephine biopsy specimens of Multiple Myeloma, diagnosed at our hospital.
- Registration Number
- CTRI/2018/03/012755
- Lead Sponsor
- Dharamshila Hospital and Research Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
50 cases Multiple Myeloma diagnosed at our hospital will be examined and studied.
Exclusion Criteria
The following cases are excluded-
1)Post Chemotherapy (CT) patients
2)Post Radiotherapy (RT) patients
3)Plasmacytoma cases
4)Plasma cell leukemia cases
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To estimate the proportion of the proliferating (Ki67 expressing) plasma cells in a series of patients with multiple myeloma.Timepoint: at the end of the every month within study duration
- Secondary Outcome Measures
Name Time Method Clinico-pathologic correlation of Ki-67 index with various parameters viz. age, sex, performance status, hematological parameters (hemoglobin, total leukocyte count, platelet count and E.S.R.), biochemical parameters (total protein, albumin, A:G ratio etc.), number of osteolytic lesions, the Durie-Salmon staging, the International staging system, plasma cell percentage, plasma cell infiltration pattern in bone marrow and degree of fibrosis in bone marrowTimepoint: at the end of the every month within study duration